You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
麗珠集團(000513.SZ)及下屬附屬公司共有186個產品納入醫保目錄
格隆匯 08-21 19:41

格隆匯8月21日丨麗珠集團(000513.SZ)公佈,近日,國家醫療保障局發佈了新版《國家基本醫療保險、工傷保險和生育保險藥品目錄》(醫保發[2019]46號,“《醫保目錄》”)。

公司及下屬附屬公司共有186個產品納入《醫保目錄》,其中甲類95個,乙類91個。納入《醫保目錄》的主要重點產品有:艾普拉唑腸溶片、注射用醋酸亮丙瑞林微球、參芪扶正注射液、抗病毒顆粒、雷貝拉唑鈉腸溶膠囊、注射用伏立康唑、注射用尿促性素、馬來酸氟伏沙明片等。

此次新進入《醫保目錄》的品種為鹽酸哌羅匹隆片。

此次退出國家《醫保目錄》的公司產品共計21個,其中18個產品早已停產停銷,退出的在產在銷產品2019年1-6月合計銷售收入約佔公司2019年1-6月營業總收入的4.58%,因此對公司的經營狀況不構成重大影響。退出的主要品種為鼠神經生長因子。

此次《醫保目錄》還調整了部分藥品的醫保分類以及修訂了部分藥品的備註信息內容,其中,分類調整的公司產品主要有枸櫞酸鉍鉀顆粒、纈沙坦膠囊以及單硝酸異山梨酯片,均由原醫保乙類藥品調整為醫保甲類藥品;備註信息修訂的公司產品主要有艾普拉唑和參芪扶正注射液。

此次公司多數重點產品,特別是個別獨家產品被納入新版《醫保目錄》,將會獲得醫療機構的積極採購及臨牀應用,有利於促進該等產品的市場推廣,從長期看,將對公司的經營業績產生積極的影響,同時,因新版《醫保目錄》的正式執行還需待時日,因此,短期內尚不會對公司的經營業績構成重大影響,敬請廣大投資者注意投資風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account